The central importance of the tumor suppressor Retinoblastoma protein (Rb) in cell-cycle progression makes its regulation a focal point for diverse biological processes, as evidenced by recent work described in this issue's Molecular Biology Select. These findings reveal new insight into Rb's involvement in tissue regeneration and differentiation, as well as previously unrecognized mechanisms of Rb regulation.
Fat Chance for Bone Formation
Previous in vitro studies suggested that Rb plays a critical role in the decision of meschenchymal cells to become adipocyte or bone cells, but in vivo evidence for this hypothesis has been lacking. Calo et al. (2010) now show that Rb gives meschenchymal cells the extra nudge they need to commit to becoming bone-forming osteoblasts. Without Rb, these cells are more likely to differentiate into brown fat cells, leading to reduced levels of calcified bones and increased levels of brown adipose tissue in mice. To sort out how Rb regulates the fate of the meschenchymal cells during development, the authors engineered mice with the RB1 gene and/or the p53 gene deleted only in uncommitted meschenchymal cells. As expected, animals missing the tumor suppressor p53 develop multiple types of tumors, including osteosarcomas. Combining the p53 mutation with a deletion of one RB1 allele increases the frequency of osteosarcomas, whereas deletion of both RB1 alleles shifts the tumor distribution away from osteosarcomas towards brown fat tumors. Thus, Rb regulates the fate of meschenchymal cells in a dose-dependent manner. These results are surprising given that the majority of human osteosarcomas contain RB1 mutations. The authors speculate that osteosarcoma tumors most likely arise from cells already committed to becoming osteoblasts, and mutations in RB1 promote dedifferentiation of these cells and thus tumorigenesis. 
Rb Gets Caught in a Custody Battle
Rb is caught in a tug-of-war between cyclin-dependent kinases (Cdks) that inactivate it by phosphorylation to permit cell-cycle progression and phosphatases that remove the modification to promote cell-cycle arrest. New findings of Hirschi et al. (2010) demonstrate that this conflict is waged over the same binding interface of Rb. They provide structural evidence that the phosphatase PP1 interacts with Rb in a region previously shown critical for the interaction of Rb with Cdks. They further show that PP1 can suppress the activity of Cdk2-cyclin A toward Rb to block cellcycle progression in a human osteosarcoma cell line, and that the complex of PP1 and Rb appears to be stable, or at least more prevalent, at mitotic exit. Among the interesting questions this work raises is, what factors determine the outcome of PP1 and Cdk competition? The authors propose that concentration and subcellular localization of the competing proteins likely play a role, but it remains unclear how this molecular dispute is settled under specific biological circumstances, for example after DNA damage. A. Hirschi et al. (2010) 
Methylation Moves to the Front of the Line
Although first reported more than 30 years ago, methylation of protein N termini (a-N-methylation) remains a poorly understood protein modification. Thus, the recent identification by Schaner-Tooley et al. (2010) of an enzyme that catalyzes the reaction promises to accelerate understanding of the modification's functions. The authors use methylation of a known target of a-N-methylation called RCC1 (a Ran guanine nucleotide exchange factor) as an indicator of the presence or absence of the enzymatic activity from fractionated HeLa cell nuclear extracts. Fractions with methyltransferase activity were subjected to mass spectrometry, leading to the identification of the methyltransferase responsible, which the authors name NMRT (N-terminal RCC1 methyltransferase). The NMRT crystal structure facilitated the modeling of substrate recognition, and further analysis defining the consensus sequence for target recognition suggested Rb as a potential substrate. Subsequent assays provide evidence that Rb is modified by a-N-methylation, at least in some cell types. a-N-methylation of RCC1 promotes stable association with chromatin, and loss of NMRT or the absence of the RCC1 methylation results in defects in mitosis. In contrast, the purpose of Rb a-N-methylation remains a tantalizing mystery. Regardless of whether Rb a-N-methylation is relevant to its roles in cell-cycle control, the discovery of NMRT opens a door through which others will likely follow. Are there other a-N-methyltransferases? And if so, is their substrate specificity similar to NMRT? The answer may be an indicator of whether this modification is an exotic posttranslational event or might instead be considerably more common than previously appreciated. Another compelling question is whether there are a-N-demethylases that reverse the modification. C.E. Schaner-Tooley et al. (2010) . Nature. Published online July 29, 2010 July 29, . 10.1038 Robert P. Kruger X-ray crystal structure of Rb (magenta) in complex with the PP1 catalytic domain (gray). Image courtesy of S. Rubin.
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